Diabetes

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.

Oral semaglutide shows promising cardiovascular benefits for type 2 diabetes patients, reducing major adverse events by 14% in the SOUL trial.

CagriSema shows promising weight loss and metabolic benefits in recent trials, offering new hope for obesity and type 2 diabetes management.

Semaglutide shows promise in enhancing walking ability and reducing disease progression in patients with type 2 diabetes and peripheral artery disease.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

New research reveals how individual blood glucose responses to carbohydrates vary, highlighting the importance of personalized dietary approaches for diabetes management.

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

Ranibizumab injection (Susvimo; Genentech) could offer long-lasting vision preservation and reduce the need for frequent injections in patients with diabetic retinopathy.

Research reveals pioglitazone, a diabetes drug, may slow prostate cancer progression, offering new hope for patients with both conditions.

Diabetic ketoacidosis poses serious risks for patients with diabetes, requiring urgent treatment to prevent life-threatening complications and ensure recovery.

Motivational interviewing serves as a beneficial strategy to enhance medication adherence and improve patient outcomes in diabetes management.

Patients should understand that routine skin care is an important facet in the overall management of diabetes.

New research reveals a promising strategy to slow type 1 diabetes progression by targeting inflammation with an existing psoriasis drug.

Research shows comprehensive medication reviews enhance medication adherence in those with type 2 diabetes, highlighting pharmacists' vital role in improving health outcomes.

New research reveals how high blood sugar from type 2 diabetes alters brain function, mimicking early Alzheimer symptoms and impacting memory.

Hospital compounding is gaining renewed attention amid drug shortages, regulatory changes, and labor challenges, prompting pharmacies to leverage advanced technology for safer, more efficient, and compliant medication preparation.

Data show that the system is also the most accurate continuous glucose monitor (CGM).

Pharmacists play a key role in educating patients and prescribers on the selection, use, and management of GLP-1 receptor agonists in diabetes care.

Pharmacists can address micronutrient deficiencies, aiding those with type 2 diabetes as they face a higher risk.

Optimal glycemic control and medication delivery rely upon proper tools and techniques.

Pharmacists can help patients with diabetes save money.

In a debate at the 2025 APhA Annual Meeting, speakers highlighted GLP-1s’ advantages in stroke prevention and weight loss vs SGLT2s’ superiority in heart failure, CV death reduction, and renal protection.

Two pharmacists at the 2025 APhA Annual Meeting debate the role of continuous glucose monitoring (CGM) for non-insulin users, highlighting evolving guidelines, emerging clinical evidence, cost and coverage challenges, and the need for further research to justify widespread adoption.

Health care professionals in the study found it challenging to manage the complexities of disordered eating in patients with type 1 diabetes alongside their other responsibilities.

An expert roundtable discussed what consumers and pharmacists should be aware of as compounded versions of glucagon-like peptide-1 receptor agonists continue to proliferate.

Community pharmacists are uniquely positioned to assist with diabetes management using CGM devices.

Treatment with HTD1801 resulted in significant reductions in the hemoglobin A1c level and improved key cardiometabolic and liver parameters.

The new data emphasize the fundamental differences in management and associated complications with each form of diabetes.